Objective: Chronic sleep deficiency is associated with early mortality. In the epileptic population, there is a higher prevalence of sleep disorders, and individuals with severe refractory epilepsy are at greater risk of premature mortality than the general population. Sudden unexpected death in epilepsy affects 1:1000 cases of epilepsy each year. Ketogenic diet (KD) treatment is one of the few effective options for refractory seizures. Despite KD reducing seizures and increasing longevity in Kv1.1 knockout (KO) mice, they still succumb to sudden death. This study aims to determine whether (1) the rest profiles of KO and KD-treated KO (KOKD) mice resemble each other as a function of either age or proximity to death and (2) the timing of death correlates with acute or chronic changes in rest. Methods: Noninvasive actimetry was used to monitor rest throughout the lives of KO and wild-type (WT) littermates administered standard diet or KD. Results: As KO mice age, rest is reduced (P < .0001). Rest is significantly improved in KDKO mice (P < .0001), resembling WT values at several ages. When age is removed as a variable and data are realigned to the day of death, the rest profiles of KO and KOKD groups worsen to similar degrees as a function of proximity to death. The amount of rest acutely is not sensitive to the timing of death, whereas chronic rest deficiency profiles (10-15 days prior to death) of both groups were indistinguishable. Chronic accumulation of rest deficiency over the final 15 days was associated with 75% of deaths. Significance: Our data suggest that the accumulated rest deficiency is associated with sudden death in Kv1.1 KO mice. These data (1) support the proposed clinical hypothesis that chronic sleep deficiency may be associated with early mortality in epileptic patients and (2) warrant future preclinical and clinical studies on sleep monitoring in epileptic patients.
| INTRODUCTION
Epilepsy is a broad spectrum neurological disease characterized by recurrent and unprovoked seizures. It is the fourth most common neurological disorder affecting approximately 50 million people globally. 1 It is estimated that about 1 in 26 people will develop epilepsy during their lifetime. 2 Within the epilepsy population, there is an increased risk for comorbid sleep disorders, resulting in approximately 30% of epileptic patients experiencing inadequate sleep. 3 Sleep deprivation can worsen seizures and the seizures themselves can further disrupt sleep, thus promoting a negative feed-forward cycle. 4, 5 Individuals (with and without epilepsy) who suffer from chronic sleep deficiency are more likely to experience cognitive impairments, cardiac arrhythmias, and apnea and to have shorter lifespans. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] There is a higher risk of premature mortality in epilepsy than the general population, with the incidence rate of sudden unexpected death in epilepsy (SUDEP) approximating 1 in 1000 cases every year. 16, 17 Risk factors associated with SUDEP include severe and refractory seizures, lower intelligence quotient, and cardiac arrhythmias. 18 Despite the role of chronic sleep deficiency in seizure exacerbation, cognitive impairments, cardiac arrhythmias, and mortality, whether sleep deficiency is associated with SUDEP remains unknown.
To begin to determine whether insufficient sleep is associated with SUDEP risk, we selected a model of epilepsy with comorbid sleep disorders and sudden death. Functional mutations in the Kcna1 gene, which encodes for the alpha subunit of the Kv1.1 channel (a delayed rectifier, voltage-gated potassium channel) in humans and mice is associated with episodic ataxia, partial epilepsy, sleep disorders, and sudden death in epilepsy. 5, [19] [20] [21] [22] [23] [24] [25] Infrared telemetric actimetry was implemented immediately after weaning throughout life until sudden death occurred in Kv1.1 knockout (KO) mice. Here, we aimed to determine whether: (1) the rest profiles of KO mice worsened as a function of age; (2) a treatment known to improve longevity in KO mice, the ketogenic diet (KD), influenced the rest parameters (The KD is a high fat:low carbohydrate/protein diet effective in treating refractory seizures and improving sleep problems in epileptic patients and animal epilepsy models. 21, [25] [26] [27] [28] [29] [30] [31] [32] We recently reported that longevity increased by approximately 47% in KO mice treated with the KD; however, these mice still experienced sudden death. 25 Here, we specifically determined whether the rest profiles of KO and KD-treated KO (KOKD) mice resemble each other as a function of age or proximity to death.); and (3) the timing of death correlated with either acute or chronic changes in rest.
| MATERIALS AND METHODS

| Animals
C3HeB/FeJ KO mice and wild-type (WT) mice were reared in a quiet room on a 12-hour light/dark cycle (lights on at Zeitgeber time [ZT] 00:00 hours) at Creighton University's animal resource facility and provided food and water ad libitum. Genotype was determined from tail clips by Transnetyx (Cordova, TN, USA). KO mice and their WT littermates were weaned onto either a standard diet (SD) or a KD (6.3:1, fat to carbohydrates plus proteins; Bio-Serv F3666, Frenchtown, NJ, USA) at postnatal day 21 (P21). Experiments were conducted in accordance with the guidelines of the National Institutes of Health and approved by the institutional animal care and use committee.
| Actimetry
We utilized continuous infrared telemetric actimetry and switch-closure activity monitoring (Vital View data acquisition system; Mini Mitter Company, Bend, OR, USA), a proven high-throughput noninvasive method to accurately assess rest and activity patterns (See Figure S1 ).
| Statistics
We performed the statistical analysis using Prism 6 (GraphPad Software, La Jolla, CA, USA). Data were expressed as mean AE standard error of the mean and analyzed using analysis of variance (ANOVA) with Dunnett multiple comparison post hoc test unless otherwise noted.
3 | RESULTS 3.1 | As KO mice aged, the number of rest epochs was reduced
The first aim of this study was to identify whether rest profiles worsen as a function of age. The representative actograms in Figure 1A depict the differences between the restactive cycles of KO mice and WT littermates. The total number of daily rest epochs was determined and plotted for each animal ( Figure 1B ). When compared within genotype, WT rest did not change with age ( Figure 1C ). In contrast, there was a prominent reduction in the number of rest epochs as KO mice aged, beginning at P38. Post hoc analyses indicated that when compared to their youngest age, the number of KO rest epochs was reduced by 32% at P42 and by 47% at P50 ( Figure 1C ). Between genotypes, the rest values of KO and WT mice were similar at P26. However, with age KO mice rested for significantly fewer epochs when compared to their WT littermates beginning at P30 ( Figure 1C ).
| KD treatment increased rest of KO mice
The second aim of the study was to determine whether the rest profiles of KO and KOKD mice resemble each other as a function of age. Overall, KD treatment significantly improves rest in KO mice. However, the polynomial nonlinear regression used to fit KOKD data indicates temporal phasic influence of KD treatment on rest in KO mice ( Figure 1C ). During the first 2 weeks of either KD or SD, KO groups did not differ. Compared with the youngest age, protective effects became apparent when KOKD mice reached P38. At P42, KOKD mice experienced~25% less rest compared to WT and 31% less rest at P50. During this time, the trajectory of rest reduction for KO and KOKD groups were similar. Interestingly, once KOKD mice reached P50, the negative trajectory of the rest decline halted and the number of daily rest epochs stabilized with no difference between P50 and older age groups. There was a significant difference among groups in the daily number of transitions from rest-active; however, transitions remained stable across age ( Figure 1D ). Collectively, these data indicate that rest diminishes with age in KO. In addition, KD treatment provides some protection against the age-related severity of the rest decline in KO mice.
| Rest diminished as KO and KOKD mice approached death
In our colony, 100% of KO mice died prematurely. KD treatment significantly increased longevity of KO mice from P49 AE 2 days to P68 AE 2 days ( Figure 2A) ; however, KOKD mice still experienced premature mortality. Thus, we next determined whether the rest profiles of KO and KOKD mice resemble each other as a function of proximity to death. Age was removed as a variable from the subsequent analyses, and the data were realigned starting at the day prior to sudden death (PTD). The rest epoch data were analyzed retrospectively to determine whether the severity of the rest decline that occurred immediately prior to death was similar between groups. Beginning at 1 day PTD and going backward to younger ages, the daily beginning at postnatal day (P38; F 7,252 = 4.99, P < .0001) and when compared to WT (F 1,252 = 365.9; P < .0001). KD treatment of KO mice improved rest (F 3,533 = 96.00; P < .0001). Within-group analyses indicate that effects were not linear (F 12,536 = 3.650; P < .0001). Rest does not change among P50 and older ages in KOKD mice (F 7,140 = 1.03, P = .4). Data are expressed as mean AE standard error of the mean (SEM). Asterisks indicate significant difference within group from P26 value (red = KO, green = KOKD): *P < .05, **P < .01, ***P < .001, ****P < .0001. Plus symbols indicate statistical difference from KO (red KO 9 WT; green KO 9 KOKD): +P < .05, ++P < .01, +++P < .001, ++++P < .0001. D, The daily number of rest-active transitions were pooled for each age bin. KO mice have significantly higher rest-to-wake transitions when compared to WT controls beginning on P30 (F 3,534 = 98.6, P < .0001). Data are expressed as mean AE SEM; ****P < .0001 indicates statistical difference compared to WT. KO mice died on P50 AE 2 days; thus, n = 5 KO mice from P26 to P46, n = 3 at P50, n = 2 at P54, and n = 1 at P57. At all ages, WT n = 5, KOKD = 8, and WTKD = 6 rest epochs were repooled into 4-day bins. WT and WTKD rest were stable at all ages. Irrespective of age, the number of rest epochs significantly changed as both KO and KOKD groups approached sudden death. At the youngest ages (ie, furthest from death), both KO and KOKD groups resembled WT values. After approximately 8 days of resting at WT levels (from 25 to 32 days PTD), KO mice began experiencing significant and chronic reduction of rest epochs ( Figure 2B ). In contrast, KD treatment allowed KO mice to rest at WT levels for approximately 30 days (from 29 to 56 days PTD). The onset of diminishing rest began at 25-28 days PTD and became chronic thereafter ( Figure 2B ). During the weeks prior to sudden death, the rest profiles of KO and KOKD mice were indistinguishable. These data indicate that a subject that rests~30% less than WT will die within 24 days (KO, 29 AE 5% and KOKD, 30 AE 7%) and a subject that rests~40% less than WT will die within 12 days (KO, 41 AE 5% and KOKD, 40 AE 5%) in this model of epilepsy, sleep disorders, and SUDEP.
Within-group comparison was used to determine how severe and for how long the chronic reduction of rest occurred prior to death. When compared to 25-28 days PTD, KO mice were the most deficient in rest during the final 12 days PTD ( Figure 2C ). Following onset of rest reduction for KOKD mice, their rest profiles resembled the KO group prior to sudden death, with the lowest levels occurring during the final 16 days PTD ( Figure 2C ).
| Acute rest epochs from 1 or 2 days PTD is not unique to the time of death
Next, we determined whether the number of rest epochs that occurred acutely during 1 or 2 days PTD was unique within each group to the timing of death. As the number of rest epochs declined, mortality increased to similar degrees for the KO and KOKD groups ( Figure 3A) . However, the mortality plot inaccurately suggests that KO mice will die if they rest for only 50 or fewer epochs. This is depicted by the range of the raw data (ie, the number of rest epochs for each animal for each day) shown in the scatterplot superimposed on the lower portion of the percentage mortality graph in Figure 3A . The scatterplot highlights the frequency of each daily rest epoch number in relation to mortality. The occurrence rate for the daily rest epoch value at 1 day PTD was calculated to determine how often that amount of rest or less occurred throughout the lifespan of that animal or any other animal within the same group. Resting for 50 or fewer epochs occurred in 7% of the KO rest periods and death did not follow. As depicted in Figure 3B , the number of rest epochs at 1 day PTD occurred 10%-39% of the time and death did not follow. Similarly, the rest experienced by KOKD mice at 1 day PTD occurred 7%-98% of the time and death did not follow ( Figure 3B ). These data suggest that the amount of rest experienced 1 day PTD is not unique to the occurrence of death.
Interestingly, when considering the total amount of rest experienced 2 days PTD, KOKD mice died with significantly more rest when compared to KO mice ( Figure 3C ). The range of occurrence rates for both KO and KOKD mice were common through life ( Figure 3D ). Collectively, these data suggest that the amount of rest during 1 or 2 days PTD is not unique to the occurrence of death.
| Rest deficiency
In clinical sleep studies that focus on how much sleep an individual is deprived of each night, the terms (1) partial and full sleep deprivation distinguish between a few hours and an entire night of deprivation and (2) acute versus chronic indicates the duration of the deprivation protocol (ie, for a few nights vs many weeks or months). To increase translational relevance, we assessed the deficiency of rest. Data were plotted in days PTD and analyzed prospectively to assess the accumulation of rest deficiency over time. This cumulative deficiency was analyzed during 3 time frames: (1) during their lifespan (Figure 4) , (2) 
| KOKD mice accumulate more rest deficiency prior to death
The rest deficiency was determined for each rest phase over the lifespan of each subject ( Figure 4A ). Cumulative deficiency was plotted against days prior to death. At the youngest ages, KO and KOKD groups resembled WT; thus, their deficiency was near 0. Cumulative rest deficiency was significantly correlated with PTD for KO and KOKD groups. Interestingly, KOKD mice experienced more rest deficiency throughout their lives when compared to KO mice. However, when normalized to lifespan, the ratio of rest deficiency prior to death did not differ between KO and KOKD mice ( Figure 4B ). These data indicate that both groups experienced similar overall amounts of rest deficiency when normalized to longevity. These data also indicate that once KO mice accumulate 648 epochs of deficiency, mortality will occur within 19 days ( Figure 4C , lower red horizontal line and vertical intersection). In addition, by 1724 epochs, 80% of mice have died and the remaining will within 6 days (Figure 4C , upper red horizontal line and vertical intersection). Similarly, once KOKD mice accumulate 1376 epochs of deficiency, mortality occurs within 33 days; by 2767 epochs, 71% of mice have died and the remaining will die within 19 days ( Figure 4C, green lines) .
Monitoring the lifetime cumulative rest deficiency is only feasible in animal models and provides useful information. However, this type of monitoring is not feasible in the clinic. Thus, we analyzed the chronic accumulation of rest deficiency over manageable time frames of 10-and 15-day increments.
3.7 | Chronic accumulation of rest deficiency over the 10 days PTD is sensitive to the timing of death for 58% of subjects Both KO and KOKD groups experienced similar degrees of rest deficiency during the final 10 days PTD ( Figure 5A ). This is apparent with similar areas under the curve (AUCs; KO, 3707 AE 776 and KOKD, 3209 AE 448; P = .9) and by the single curve fit when assessing the cumulative probability of death by their cumulative rest deficiency (F 2,8 = 3.0, P = .1; Figure 5B ). These data indicate that although KOKD mice live significantly longer, their 10-day rest profile prior to death resembles KO values.
To control for whether these amounts of rest deficiency had occurred earlier in each subject's life, rest deficiency over 10 days was examined at 3 earlier time Wild-type (WT) and WTKD rest epochs did not differ and were therefore combined (WT all, blue line). The vertical bar at the right indicates sudden death for the KO and KOKD groups. The number of rest epochs significantly changed as both KO and KOKD groups approached sudden death (F 7,623 = 4.2, P < .0002). Red asterisks indicate KO group differs significantly from WT at all ages spanning the blue lines (in the middle of the graph). Green asterisks indicate KOKD group differs significantly from WT at all ages spanning the blue line (bottom of graph). C, KO (left graph, red line) and KOKD (right graph, green line) data were separated from the graph in B and replotted to highlight the within-group differences (analysis of variance with Tukey multiple comparisons post hoc test). All data were compared to the last bin when rest levels resembled WT levels (arrows). The rest deficiency occurred during the final 12 days prior to sudden death (PTD) and 16 days PTD in KO and KOKD mice, respectively (F 7,623 = 4.16, P < .005) and remained low until death. Data are expressed as mean AE standard error of the mean; *P < .05, **P < .01, ***P < .001, ****P < .0001
points: at the beginning of data acquisition and twice in the middle of the animal's life (equidistant from the first and last time points). These within-subject 10-day samples were compared to the final 10 days PTD for each subject ( Figure 5C ; the asterisks indicate the data from the final 10 days PTD time point). This graph depicts the high intersubject variability within each group and thus highlights the importance of using a within-subject design to analyze the data. The fractional accuracy of this metric was determined within subject by whether death followed the highest amount of cumulative rest deficiency (indicated by a value of 1; Figure 5D ). Using this metric, 3/5 KO and 4/7 KOKD mice died following the greatest amount of accumulated rest deficiency. In addition, 4 of the remaining 5 mice died immediately following their second largest amount of rest deficiency. The data suggest that each subject reaches a critical mass of accumulated rest deficiency prior to death. When data from the final 10 days PTD was compared to the first 10 days of data acquisition (baseline), KO mice died when rest deficiency was 1.9 AE 0.3-fold higher than baseline. Interestingly, KOKD mice died when deficiency was 3.6 AE 0.8-fold greater than baseline (however, this does not differ from KO; P = .08). 1 day PTD or (C, D) 2 days PTD. A, The number of rest epochs from 1 day PTD was plotted against mortality and did not differ between groups (P = .09; log-rank Mantel-Cox text). For Kv1.1 knockout (KO) mice, the number of rest epochs 1 day PTD was 50, 57, 60, 69, and 91. For KO with ketogenic diet (KOKD) mice, the number of rest epochs 1 day PTD was 38, 65, 74, 83, 145, 155, and 195. The range of the raw data (ie, the number of rest epochs for each animal for each day) is shown in the scatterplot superimposed on the lower portion of the percentage mortality graph (red for KO and green for KOKD). B, The occurrence rate for the daily rest epoch value at 1 day PTD was calculated to determine how often that amount of rest or less occurred throughout the lifespan of that animal or any other animal within the same group. C, The number of rest epochs that occurred during 2 days PTD were summed and plotted against the mortality (P < .0005, log-rank Mantel-Cox test). D, The occurrence rate for the daily rest epoch value during 2 days PTD was calculated to determine how often that amount of rest or less occurred throughout the lifespan of that animal or any other animal within the same group (ranges: KO, 3%-33% and KOKD, 27%-96%)
| Chronic accumulation of rest deficiency over the 15 days PTD is sensitive to the timing of death for 75% of subjects
To determine whether data from 15 days PTD increased the fractional accuracy, we conducted the same analyses as described above. Similar degrees of rest deficiency occurred for both groups during the final 15 days PTD (similar AUC: KO, 7771 AE 1182 and KOKD, 7192 AE 1092; P = .8, Mann-Whitney test; Figure 6A ). Although KD treatment significantly increased longevity ( Figure 6B ), when age was removed as a variable, the amount of rest deficiency both groups accumulated over 15 days PTD was indistinguishable (F 2,8 = 4.0, P = .06; Figure 6C ).
To control for whether the amounts of deficiency had occurred previously, 3 earlier time points were compared to the final 15 days PTD for each subject ( Figure 6D ).
These data indicate that KO mice died with at least a 558-epoch deficiency (red vertical line); however, 85% of KO samples were greater than this. Interestingly, this value did not change much with KD treatment. KOKD mice died with at least a 601-epoch deficiency (green vertical line), with 57% of KOKD samples being greater than this. Interestingly, of all the 15-day samples analyzed for both groups, note the lowest KO deficiency sample (blue dashed line at 396 epochs). KD treatment did allow 4/7 mice to experience less rest deficiency when compared to the lowest KO value. The fractional accuracy of this metric illustrates that 4/5 KO and 5/7 KOKD mice died following the greatest amount of accumulated rest deficiency ( Figure 6E ). In addition, the remaining 3 subjects died immediately following their second largest amount of rest deficiency.
Compared to baseline, there was a significant fold increase among the 2nd, 3rd, and final samples for both KO and KOKD groups (F 2,20 = 4.18; P < .05; 2-factor ANOVA; Figure 6F ). Arrows indicate that only 2/12 mice did not have an increase from the 3rd sample to the final sample. Overall, KO mice died when rest deficiency was F I G U R E 4 Kv1.1 knockout (KO) mice with ketogenic diet (KOKD) accumulate more rest deficiency prior to sudden death (PTD). A, Optimal rest was defined as the stable wild-type (WT) value throughout life (168 AE 6 rest epochs, n = 20-40 periods per mouse, 10 mice). Therefore, we assessed the rest deficiency of KO mice, or the amount of rest KO mice were deprived of during each rest phase relative to age-matched WT controls. Data were aligned at the day of death. The number of rest epochs for each rest period of KO and KOKD mice was subtracted from the WT value (168 rest epochs) to yield the rest deficiency for each period PTD. Data were averaged within group, and the cumulative rest deficiency was prospectively plotted for each day PTD over the animal ' 
| DISCUSSION
To our knowledge, this is the first study to assess whether deficiencies in rest are associated with sudden death in a preclinical epilepsy animal model in which mortality occurs during a predictable window. We report that (1) as KO F I G U R E 5 Chronic accumulation of rest deficiency over the final 10 days prior to sudden death (PTD) is sensitive to the timing of death for 58% of subjects. A, Cumulative probability of rest deficiency (in epochs) significantly correlated with days PTD for Kv1.1 knockout (KO; R 2 = 0.99, P < .0001) and KO with ketogenic diet (KOKD) groups (R 2 = 0.99, P < .0001; Pearson correlation). Linear regression indicates no statistical difference between slopes (F 1,116 = 3.22, P = .08) or y-intercept (F 1,117 = 3.6, P = .06). Data are expressed as mean AE standard error of the mean. B, Histogram for the probability of death as a function of the cumulative rest deficiency for 10 days PTD was generated. A cumulative Gaussian nonlinear regression analysis fit both datasets with a single curve (R 2 = 0.92 for KO and 0.93 for KOKD). C, Samples of accumulated deficiency in rest over 10 days were taken at 3 other time points throughout each animal's life in addition to the final 10 days PTD. Deficiency over the first 10 days is represented as the first bar of the 4-bar clusters, and deficiency over the final 10 days by the last bar (denoted by the asterisks). KO mice are in red, and KOKD mice are in green. D, Fractional depiction of whether the highest amount of rest deficiency was accurately associated with death when considering the ranking of within-subject samples from highest to lowest deficiency in rest. E, The fold change in rest deficiency during the 10 final days PTD when compared to the first 10 days of data acquisition mice age, rest is reduced when compared within group to younger ages and between groups to age-matched WT mice; (2) rest is improved in KO mice treated with the KD; (3) when aligning the data points at the time of death, the rest profiles of KOKD mice resemble those of KO mice; (4) acute levels are rest (during the last day or 2 days F I G U R E 6 Chronic accumulation of rest deficiency over the final 15 days prior to sudden death (PTD) is sensitive to the timing of death for 75% of subjects. A, Cumulative probability of rest deficiency (in epochs) significantly correlated with days PTD for Kv1.1 knockout (KO; R 2 = 0.99, P < .0001) and KO with ketogenic diet (KOKD) groups (R 2 = 0.99, P < .0001; Pearson correlation). Linear regression indicates no statistical difference between slopes (F 1,176 = 2.5, P = .12) or y-intercept (F 1,177 = 2.0, P = .16). Data are expressed as mean AE standard error of the mean. B, Cumulative probability of mortality as a function of age for KO and KOKD groups (the histogram of the frequency distribution was analyzed using a cumulative Gaussian nonlinear fit; P < .0001). C, Cumulative probability of mortality as a function of cumulative rest deficiency. Gaussian nonlinear regression analysis fits both datasets with a single curve (R 2 = 0.91 for KO and 0.93 for KOKD). D, Samples of accumulated deficiency in rest over 15 days were taken at 4 time points. Deficiency over the first 15 days is represented as the first bar of the 4-bar clusters, and the final 15 days is the last bar (denoted by the asterisks). KO mice are in red, and KOKD mice are in green. The blue dashed line depicts the lowest amount of rest deficiency experienced by KO mice. The horizontal lines indicate the least amount of deficiency at 15 days PTD for KO (red) and KOKD (green) groups. E, Fractional depiction of whether the highest amount of rest deficiency was accurately associated with death when considering the ranking of within-subject samples from highest to lowest deficiency in rest. F, The fold change in rest deficiency compared the 2nd, 3rd, and final 15-day samples to the first 15-day sample. The first sample began at data acquisition and was considered baseline. The final sample was 15 days PTD. Arrows indicate subjects in which the ratio of rest deficiency was not increased during the final 15-days PTD PTD) are not sensitive to the timing of death; (5) the chronic rest deficiency profiles at 10 and 15 days prior to death were similar for KO and KOKD groups; and (6) the chronic accumulation of rest deficiency over the final 15 days was associated with 75% of deaths (9/12 mice). On average, mice died when rest deficiency was 1.5-fold (KO) and 2.8-fold (KOKD) higher than baseline. These data highlight the importance of using a within-subject design to analyze the data due to the high intersubject variability within each group. There is a dearth of knowledge regarding whether sleep problems precede/exacerbate/promote SUDEP risk factors and/or SUDEP, and this is largely because it is not feasible for clinical studies to be designed to monitor rest as SUDEP approaches and there is a lack of preclinical studies in the relatively few and imperfect animal models. Here, we provide preclinical data using the KO mouse model, which offers many advantages including: (1) the age of epilepsy onset is known, as KO mice develop spontaneous behavioral seizures during the third postnatal week; (2) the seizure phenotype is well characterized and generalizable (temporal lobe, idiopathic and juvenile epilepsies); (3) sleep disorders have been well characterized in KO mice; (4) we and others have demonstrated that KO mice exhibit multiple risk factors for SUDEP, including severe and frequent seizures (myoclonic, unilateral and bilateral clonic, generalized tonic-clonic [GTC]) and cardiac arrhythmias; and (5) KO mice experience premature death during the 6th postnatal week on average. 5, [19] [20] [21] [22] [23] [24] [25] 34, 35 This known lifespan allows for lifelong monitoring of endpoints and subsequent retrospective analyses. Here, we report that KO mice have increased fragmentation and rest deficiency, supporting our previous findings in adult KO mice. 5, 21 Interestingly, the fragmentation did not have a progressive ontogeny. At the youngest ages assessed, KO mice experienced more rest-to-wake transitions when compared to WT mice and this difference between genotypes remained constant throughout life. A previous report found that during the time period analyzed herein, KO mice experience minimal rapid eye movement (REM) sleep; thus, it is likely the transitions are predominantly between non-REM (NREM) rest and wake. 5 Rest fragmentation may contribute to promoting SUDEP risk factors. Increased sleep fragmentation is associated with cognitive impairments and apnea 10, 36, 37 ; however, sleep fragmentation has not been associated with worsening a seizure phenotype and/or promoting cardiac arrhythmias. Because the number of transitions did not change as a function of age, rest fragmentation does not provide temporal indication of SUDEP imminence in this model. Alternatively, our data indicate that progressive reduction in rest does precede sudden death. Seizures and sleep deprivation can exacerbate the presence of each other, thus creating a negative feed-forward cycle. 4, 5 Moreover, studies report that more severe sleep deficiency is associated with greater degree of cognitive impairment, arrhythmias, and seizure severity. Whether these changes worsen as DS mice approach death has yet to be determined. Interestingly, the number of animals that survived pentylenetetrazol (PTZ) injections and subsequent seizures positively correlated with previous sleep; sleep deprivation increased mortality and restored sleep improved survivability. 42 These data suggest that restored sleep may improve ability to recover from a severe seizure. Our current experimental design was not able to decouple whether the seizures caused the rest deficiency or whether the rest deficiency occurred independent of the seizures. Video-electroencephalographic monitoring of mice with SCN1A mutation R1648H, a genetic model for spontaneous seizures with susceptibility to febrile seizures, also indicated sleep architecture disruptions (ie, more wakefulness and less NREM and REM sleep) during time periods in which seizures were absent. 43 These data suggest that seizures were not the direct cause of sleep architecture deficiencies. In contrast, clinical and animal model studies have found that more severe seizures can trigger wake from sleep. 7, 44, 45 We have previously reported that seizures increase in severity and frequency with age, and herein we found that rest deficiency follows a similar timeline. 25 In
Knca1-null mice, severe seizures can propagate to the lateral hypothalamus, a region involved in promoting wake from sleep, and increased seizure burden (which accounts for frequency, severity, and duration) positively correlates with the severity of sleep architecture disruption. 5 Specifically, the higher the seizure burden, the longer it took for REM sleep onset to occur. Collectively, data suggest that seizures may promote wake and may be at least partially responsible for sleep disruptions. Recently, Harden et al. performed a detailed review of clinical studies concerning SUDEP and concluded that the major risk factor for SUDEP is the occurrence of GTC seizures and that risk increases with increased frequency of GTC seizures. 46 Therefore, the authors concluded that a clinical strategy to reduce SUDEP risk is to achieve freedom from seizures, in particular GTC seizures. The KD is one of the only effective, nonsurgical clinical treatments for refractory epilepsy. 32 In humans, KD treatment has been known to abolish seizures in about 13% of patients, with >50% reduction in seizures in two-thirds of patients with refractory epilepsy. 26 In PTZ and pilocarpine seizure rodent models, KD increases seizure threshold and attenuates epileptogenesis. 29, 30 In KO mice, KD treatment decreases hippocampal excitability, reduces seizures by~75%, delays GTC seizure progression, and postpones SUDEP.
21,25,31
Previously, we demonstrated that GTC seizure occurrence increases with age in KO mice, paralleling the progressive worsening of rest deficiency found here. 25 Currently, it is unknown whether the epilepsy and sleep phenotypes of KO mice have dependent (causative or negative feedback) or independent relationships. However, we have found that somnogenic drugs used to treat insomnia and other sleep disorders improve sleep and reduce seizures in KO mice. 5, 21 In addition, the KD improves REM sleep, reduces excessive daytime sleepiness, and improves the overall quality of sleep in pediatric patients with refractory epilepsy. 26, 27 KD improves the diurnal rhythms of adult KO mice. 5, 21 In the current study, the KD similarly delays the worsening of rest deficiency and SUDEP. But again, whether the KD-mediated SUDEP delay is due to effects on GTCs or rest is unclear. Before KD-treated KO mice experience SUDEP, both GTCs and rest deficiency reach levels comparable to untreated KO mice. These data suggest that the KD is not necessarily a cure in this model of severe, genetic epilepsy. Nevertheless, this study does indicate that long-term monitoring of rest/activity may enable real-time assessment of SUDEP risk. Specific subpopulations of people with epilepsy have specific identified cardiac abnormalities and genomic variants (in genes including KCNA1, SCN1A, SCN8A, HCN2, KCNQ1, KCNH2, RYR3, and HTR2C), which are postulated to be potential risk factors for SUDEP. [47] [48] [49] [50] Here, we present preclinical evidence that the onset and progressive decline in rest efficiency within subject may provide a temporal biomarker for SUDEP imminence. Future preclinical and clinical studies are required to identify the combination of genomic and physiological risk factors that may not only classify SUDEP risk, but provide temporal information regarding SUDEP imminence, and thus hopefully provide a window of opportunity for aggressive proactive and preventative treatment strategies in high-risk individuals.
